Skip to main content

MK-677 (Ibutamoren) vs DSIP

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

MK-677 (Ibutamoren)

MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.

Full details →

DSIP

Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.

Full details →

Side-by-Side Comparison

AspectMK-677 (Ibutamoren)DSIP
MechanismActs as a potent, selective agonist of the ghrelin receptor (GHS-R1a). Increases GH and IGF-1 levels without affecting cortisol. Mimics ghrelin's GH-releasing effects.Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties.
Typical DosageTypical dosing: 10-25mg taken orally once daily. Often taken at night due to sleep benefits and appetite increase.Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically.
AdministrationOral administration (capsule or liquid). Can be taken with or without food. Long half-life allows once-daily dosing.Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use.
Side EffectsIncreased appetite and water retention are most common. May cause lethargy, vivid dreams, and mild numbness. Can affect blood glucose and insulin sensitivity.May cause grogginess upon waking, vivid dreams, or temporary headaches.
Best For

What They Have in Common

Both MK-677 (Ibutamoren) and DSIP are commonly used for:

Key Differences

Unique to MK-677 (Ibutamoren):

Detailed Analysis

Both DSIP and MK-677 (Ibutamoren) are commonly used for Recovery & Healing, Sleep Quality.

Which Should You Choose?

Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.

Ready to Learn More?